CIP-TRAMADOL ER is a novel, extended-release formulation of the active ingredient tramadol, which is used for the management of moderate to moderately severe chronic pain.

Product Overview

CIP-TRAMADOL ER is enabled by controlled-release beads in an oral drug delivery technology. The novel formulation means that CIP-TRAMADOL ER delivers extended-release drug delivery properties, with once-daily dosing, supporting ease-of-use for physicians and a high level of compliance among chronic pain sufferers.  Until recently, pain sufferers typically required three to five doses of tramadol per day.  CIP-TRAMADOL ER’s attributes include rapid absorption and no food effect.

Cipher received FDA approval for CIP-TRAMADOL ER in 2010 and completed a marketing partnership with Vertical Pharmaceuticals in Q2 2011. We are currently preparing for the commercial launch of the product in the U.S in late Q3 2011. We are also awaiting a response from Health Canada to our New Drug Submission.

Market Overview

According to IMS, the U.S. market for extended release formulations of tramadol exceeded $0.15 billion which only represents 3.4% of the total tramadol immediate release and extended-release prescription market. The total tramadol market exceeded 30 million prescriptions in 2010 with an annual growth rate in prescriptions of 8.0%.